Tumor type also determines the benefits of dual VEGF-ANG2 inhibition that in lymphoid and myeloid cell populations infiltration of CD8+/CD4+ effector T cells and reprogramming of M2-like TAM to M1-like one with an anticancer phenotype, respectively, contribute to the therapeutic efficacy of dual antiangiogenic therapy (8, 39, 59). This evidence concerns the gene CD8A and neoplasm.